Study Summary
This trial will test the effects of a single session of interrupted breathing on respiratory and non-respiratory motor function in patients with ALS and healthy controls.
- Lou Gehrig's Disease
- Neuromuscular Disease
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
2 Primary · 3 Secondary · Reporting Duration: 3 Hours
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
ALS Group
1 of 2
Healthy Control Group
1 of 2
Experimental Treatment
56 Total Participants · 2 Treatment Groups
Primary Treatment: Acute Intermittent Hypoxia · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 21 - 75 · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are persons of age 20 and older being enrolled in this experiment?
"The accepted age ranges for this trial are between 21 and 75, as indicated by the inclusion criteria." - Anonymous Online Contributor
Am I eligible to participate in this clinical investigation?
"Applicants to this medical trial must have Oppenheim disease and be between 21 and 75 years old. Approximately 56 patients are needed for the study." - Anonymous Online Contributor
How many participants is the trial recruiting?
"Affirmative. Clinicaltrials.gov has records of this clinical trial, which was opened on October 1st 2018, currently seeking participants. In total, 56 individuals are required from 2 different medical sites." - Anonymous Online Contributor
Are there available places for participants in this research project?
"According to the clinicaltrials.gov website, this clinical trial is actively recruiting members for participation. Initially posted on October 1st 2018 and last updated July 25th 2022." - Anonymous Online Contributor